ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?
Feb 27, 2017
Dividend Increases/Decreases for the Week Ending February 24
Let's take a look at companies raising/lowering their dividends this week.
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
Oct 26, 2016
Commodity Price Pressures Dinging Industrial Bellwether Expectations
GE, 3M, and Caterpillar have all reduced their expectations for full-year 2016 results as a result of a challenging operating environment.
Sep 18, 2016
Dividend Increases/Decreases for the Week Ending September 16
Let's take a look at companies raising/lowering their dividends this week.
Feb 29, 2016
Dividend Increases/Decreases for the Week Ending February 26
Let's take a look at companies raising their dividends this week.
Feb 4, 2016
Industrial Earnings Roundup
Let’s take a look at the results of some industrial companies in their most recent quarters.
Mar 2, 2015
Dividend Increases for the Week Ending February 27
Let's take a look at dividend increases for the week ending February 27.
Jun 23, 2014
Why Analytical Experience Matters
Dividend growth investors -- or any investor for that matter -- shouldn’t just plug and chug numbers. An understanding of the firm and its industry is vital to making sure the company can sustainably pay dividends through the course of the economic cycle.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.